Acadian Asset Management
HUMA icon

Acadian Asset Management’s Humacyte HUMA Stock Holding History

Acadian Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,290
Closed -$55K – 1868
2024
Q3 		$55K Buy
+10,290
New +$67.8K ﹤0.01% 1768

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management's HUMA Position: Q4 2024 in Review

Acadian Asset Management sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 10,290 shares — an estimated $55K sold.

Acadian Asset Management first reported a position in HUMA in Q3 2024 and held it in 1 quarter. The position peaked at $55K in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

  • Acadian Asset Management reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 10,290 Humacyte shares in Q4 2024, an estimated $55K.
  • Acadian Asset Management first reported a position in Humacyte in Q3 2024 and held it in 1 quarter.
  • Acadian Asset Management's Humacyte position peaked at $55K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.